Estimating the Potential Public Health Value of BCG Revaccination.
J Infect Dis
; 230(1): e139-e143, 2024 Jul 25.
Article
en En
| MEDLINE
| ID: mdl-39052744
ABSTRACT
An upcoming trial may provide further evidence that adolescent/adult-targeted BCG revaccination prevents sustained Mycobacterium tuberculosis infection, but its public health value depends on its impact on overall tuberculosis morbidity and mortality, which will remain unknown. Using previously calibrated models for India and South Africa, we simulated BCG revaccination assuming 45% prevention-of-infection efficacy, and we evaluated scenarios varying additional prevention-of-disease efficacy between +50% (reducing risk) and -50% (increasing risk). Given the assumed prevention-of-infection efficacy and range in prevention-of-disease efficacy, BCG revaccination may have a positive health impact and be cost-effective. This may be useful when considering future evaluations and implementation of adolescent/adult BCG revaccination.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Tuberculosis
/
Vacuna BCG
/
Salud Pública
/
Inmunización Secundaria
Límite:
Adolescent
/
Adult
/
Child
/
Child, preschool
/
Humans
/
Infant
País/Región como asunto:
Africa
/
Asia
Idioma:
En
Revista:
J Infect Dis
Año:
2024
Tipo del documento:
Article
País de afiliación:
Reino Unido